<DOC>
	<DOCNO>NCT02349126</DOCNO>
	<brief_summary>Patients chronic HBV infection receive ARC-520 combination entecavir tenofovir evaluate safety efficacy .</brief_summary>
	<brief_title>Study ARC-520 Patient With Chronic Hepatitis B Virus</brief_title>
	<detailed_description>This single-center , open-label study ARC-520 combination entecavir tenofovir administer patient immune active chronic HBV infection . An iterative trial design anticipate potential inclusion additional cohort anticipate enrollment 60 patient . Patients sign Human Research Ethics Committee approve informed consent , meet protocol eligibility criterion continue receive daily oral entecavir ( 0.5-1.0 mg/day ) daily oral tenofovir ( 300 mg/day ) single IV injection ARC-520 . If serious adverse event ( SAE ) deem possibly probably related study drug occur point study , dose put hold pending complete review safety data sponsor Principal Investigator . Patients undergo following evaluation regular interval study : medical history , physical examination , vital sign measurement ( blood pressure , heart rate , respiratory rate , temperature ) , weight , AEs , 12-lead ECGs , concomitant medication , blood sample collection hematology , coagulation , chemistry , PK exploratory PD measure , HBV virology . Patients monitor total 12 week . Clinically significant change include AEs follow resolution , condition stabilizes , event otherwise explain , patient lose follow-up .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>Male female , 18 65 year age Written inform consent No clinically significant abnormality screening/predose 12lead ECG assessment No abnormal find clinical relevance Diagnosis immune active chronic HBV infection &gt; 6 month continuous treatment daily , oral entecavir tenofovir Pregnant lactate Acute sign hepatitis/other infection within 4 week screen Antiviral therapy entecavir tenofovir within 3 month screen Prior treatment interferon toll receptor agonist last 12 month Use anticoagulant , corticosteroid , immunomodulators , immunosuppressant Use dietary and/or herbal supplement interfere liver metabolism Use drug know induce inhibit hepatic drug metabolism Use prescription medication overthecounter product Depot injection/implant drug except birth control . Known diagnosis diabetes mellitus . History autoimmune disease Human immunodeficiency virus ( HIV ) infection Seropositive HCV , and/or history delta virus hepatitis Hypertension : blood pressure &gt; 150/100 mmHg History cardiac rhythm disturbance Family history congenital long QT syndrome/unexplained sudden cardiac death Symptomatic heart failure , unstable angina , myocardial infarction , severe cardiovascular disease History malignancy , except adequately treat basal cell carcinoma , squamous cell skin cancer , superficial bladder tumor , situ cervical cancer Major surgery within 3 month screen History alcohol and/or drug abuse &lt; 12 month screen Regularly us alcohol within past 6 month ( ie , 14 unit alcohol per week ) Evidence acute inflammation , sepsis , hemolysis Diagnosed significant psychiatric disorder Use drug abuse History allergy bee venom Use investigational agents/devices within 30 day Current participation investigational study Clinically significant gastrointestinal pathology , unresolved gastrointestinal symptom , liver kidney disease History/presence Gilbert 's syndrome , condition interfere absorption , distribution , metabolism , excretion drug Presence cholangitis , cholecystitis , cholestasis , duct obstruction Clinically significant history/presence uncontrolled systemic disease Donated blood ( 500 mL ) within 7 day prior study treatment administration History fever within 2 week screen Immunization/planned immunization live attenuate vaccine except influenza vaccine Excessive exercise/physical activity within 7 day screening/enrolment study History coagulopathy stroke within past 6 month , and/or concurrent anticoagulant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>HBV infection</keyword>
	<keyword>Hepatitis B Surface Antigen</keyword>
</DOC>